Camizestrant is an orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells. It is grouped under the following drug class(es): Antineoplastic agents. The directory classifies it as a under development API with a synthetic source/manufacturing origin. Other names for this substance include AZD-9833 and UNII-JUP57A8EPZ. Its PubChem CID is 134453496.
Camizestrant
| CAS No | 2222844-89-3 |
|---|---|
| Molecular Formula | C24H28F4N6 |
| Molecular Weight | 476.5 g/mol |
| Synonyms | N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,5-f]isoquinolin-6-yl]pyridin-3-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Camizestrant is an orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor.
The listed CAS number is 2222844-89-3.
The listed molecular formula is C24H28F4N6.
The listed molecular weight is 476.5 g/mol.
N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,5-f]isoquinolin-6-yl]pyridin-3-amine.
The source lists AZD-9833 and UNII-JUP57A8EPZ.